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ReviewCRISPR/Cas9 Genome-Editing System in Human
Stem Cells: Current Status and Future Prospects
Zhao Zhang,1 Yuelin Zhang,1 Fei Gao,1 Shuo Han,1 Kathryn S. Cheah,3 Hung-Fat Tse,1,2 and Qizhou Lian1,2,3
1Department of Medicine, University of Hong Kong, Hong Kong, China; 2Shenzhen Institutes of Research and Innovation, University of Hong Kong, Shenzhen, China;
3School of Biomedical Sciences, University of Hong Kong, Hong Kong, ChinaGenome-editing involves the insertion, deletion, or replace-
ment of DNA in the genome of a living organism using “molec-
ular scissors.” Traditional genome editing with engineered
nucleases for human stem cells is limited by its low efﬁciency,
high cost, and poor speciﬁcity. The CRISPR system has recently
emerged as a powerful gene manipulation technique with
advantages of high editing efﬁciency and low cost. Although
this technique offers huge potential for gene manipulation
in various organisms ranging from prokaryotes to higher
mammals, there remain many challenges in human stem cell
research. In this review, we highlight the basic biology and
application of the CRISPR/Cas9 system in current human
stem cell research, discuss its advantages and challenges, and
debate the future prospects for human stem cells in regenera-
tive medicine.
Background
CRISPR is a short and repeating nucleotide initially found in the
genome of bacteria and archaea, and it functions to eliminate exoge-
nous genetic elements (EGEs) that combine with Cas proteins.1,2
Three steps are required to eliminate EGEs: new spacer integration,
CRISPR/Cas combination, and degeneration (Figure 1). First, some
short nucleotides of invaders may integrate with the CRISPR loci of
the host as new spacers. The CRISPR RNAs (crRNAs) are then
transcripted to generate a crRNA/Cas complex. Finally, the EGEs
will be inactivated by the complexes under the base complementation
pairing rule. To date, three types of CRISPR-Cas immune system
have been identiﬁed with different CRISPR repeat sequences and
Cas protein proﬁle.3–5 Among them, the type II CRISPR-Cas9 im-
mune system offers strong potential in developing a totally novel
genome-editing tool for biological and medical study because it uti-
lizes RNase III in crRNA transcription and requires just one Cas9
protein to form a crRNA/Cas9 complex.5 Almendros’s group6 identi-
ﬁed the conservative NGGmotif, proto-spacer adjacent motif (PAM),
after comparing the CRISPR array of Streptococcus pyogenes. In 2013,
two articles revealed a new genome-editing stage for biological and
biomedical studies.7,8https://doi.org/10.1016/j.omtn.2017.09.009.
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Guide RNA (gRNA) and Cas9 nuclease are core components of the
CRISPR/Cas9 genome-editing system (Figure 2). Unlike the original
type II CRISPR-Cas immune system, its crRNA is eventually simpli-230 Molecular Therapy: Nucleic Acids Vol. 9 December 2017 ª 2017 T
This is an open access article under the CC BY-NC-ND license (httpﬁed to the shortest mature and functional structure without the orig-
inal crRNA processing.7,8 This simpliﬁed gRNA contains two parts: a
variable region and a basic scaffold. The former normally is composed
of 18–20 nucleotides that can bind the target DNA according to the
base complementation pairing rule. The latter is a long scaffold-like
RNA used to bind Cas9 nuclease and form a gRNA/Cas9 complex.
Then, the genome-editing system still requires three nucleotides con-
taining a PAM, NGG.6 Only the genome DNA that contains PAMs
can be identiﬁed and bound by the gRNA/Cas9 complex to generate
double-strand breaks (DSBs).Advantages
The CRIPSR/Cas9 genome-editing system offers several advantages
over the zinc-ﬁnger nucleases (ZFNs) and transcription activator-
like effector nuclease (TALEN) in human pluripotent stem cells
(PSCs) and somatic stem cells (SSCs). First, CRISPR/Cas9 is more
user-friendly than ZNF and TALEN. Several gRNAs such as synthe-
sizing primers need to be selected for using CRISPR/Cas9, because its
speciﬁcity is related only to ribonucleotide complex formation.7,8 Sec-
ond, CRISPR/Cas9 is more economical because there is little associ-
ated cost for plasmid-mediated CRISPR/Cas9. Third, as the fastest
currently available genome-editing technique, genome editing using
CRISPR/Cas9 can typically be achieved in 2 weeks.9 Finally,
CRISPR/Cas9 shows a higher editing efﬁciency than TALEN in hu-
man stem cells. Ding et al.10 demonstrated the highest genome-edit-
ing efﬁciency of 79% using CRISPR/Cas9 to edit human PSCs.Applications in Stem Cell Studies
CRISPR/Cas9-based gene manipulation, for example, gene knockout,
gene knockin, gene interference or activation, and other chromo-
some-related applications, has been widely utilized in biological and
biomedical research.11 Stem cells are indispensable for repair and
maintenance of homeostasis. In terms of tissue repair and regenera-
tion capacity, stem cell-mediated cell therapy and gene therapy
are regarded as core components of human medicine. Inordinate
manpower and ﬁnancial resources have been poured into stem cell-
related studies with many achievements. To date, several types ofhe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Overview of CRISPR-Cas Immune System
When EGEs invade the host, some fragments will integrate
into the CRISPR loci as a new spacer casually that is co-
expressed with Cas nucleases to form Cas/crRNA com-
plexes. These complexes can identify and bind with the
same EGEs during a subsequent invasion following the
base complementation pairing rule and then finally break
the EGEs.
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Reviewstem cells have been approved for clinical treatments, and many have
demonstrated remarkable outcomes in clinical trials.12 Increasing
reports conﬁrm that CRISPR/Cas9 genome editing is a powerful
tool that can promote stem cell research, from basic biological to
translational studies (Table 1).
Basic Biological Studies
Gene Knockout. The basic biology of PSCs has always been a funda-
mental component of stem cell and human developmental research.
In addition, the high differentiation capacity of human PSCs enables
their broad application. It is therefore essential to explore the intrinsic
connection between the upstream regulatory mechanism and the
downstream biological features. This can be achieved by adopting a
classic gene knockout strategy. CRISPR/Cas9 can be used to rapidly
induce genemutations in human PSCs without changing their genetic
background, making CRISPR/Cas9 a superior technique to other
gene-interfering tools (ZFN, TALEN, and RNAi).9 When a cell’s
genome DNA is broken by a gRNA/Cas9 complex, the genome repair
system is activated. One such system is non-homologous end joining
(NHEJ). This will directly ligate the broken DNA and result in the
chance of introducing a wrong base-pair deletion or insertion for
gene knockout.9 Batista et al.13 used CRISPR/Cas9 to knock out
Mettl3 in order to erase m6A modiﬁcation in human embryonic
stem cells (ESCs), which prevented the self-renewal of ESCs andMolecular Therﬁnally promoted lineage differentiation. Wang
et al.14 identiﬁed the essential role of P53 in mes-
endodermal differentiation through activation
of the Wnt3 pathway in human ESCs. Some
inducible gene knockout systems that can knock
out single or multiple genes at all the stages of
cell differentiation have recently been developed
in human PSCs.15,16
Controlling Expression. Although genome-ed-
iting-based gene knockout offers a mean by
which to study gene function, a less complex
method is sometimes required. “Dead” Cas9
(dCas9) is a variant of Cas9 nuclease whose
endonucleolytic activity has been removed. It
nonetheless retains the capacity to generate
the gRNA/Cas9 complex for binding with the
targeted DNA regions.17 Kearns et al.18 fused
different effector domains (VP64 or KRAB) to
the dCas9 and provided a platform to controlgene expression (transcription repression or activation, CRISPRi/a)
in human ESCs. In addition to straightforward controlling styles,
an inducible CRISPRi/a has been developed for human stem cell
research. Mandegar et al.19 fused a doxycycline-inducible dCas9
with KRAB and achieved conditional and reversible interference
in human induced PSCs (iPSCs) and its derived somatic cells such
as cardiac progenitors, cardiomyocytes, and T lymphocytes. Guo
et al.20 designed a doxycycline-inducible dCas9-VPR cassette to acti-
vate gene expression in human PSCs. These CRISPRi/a platforms
should provide a more convenient strategy to explore gene functions
and signaling pathways in human stem cell research, which are faster,
more convenient, andmore economical than other techniques such as
RNAi and gene overexpression.21 To achieve this, it is necessary to
ligate primer-like gRNAs into plasmids to achieve rapid transcription
activation or suppression without setting various controls or cDNA
cloning, both of which are time consuming in RNAi or gene overex-
pression. For example, Liu et al.22 utilized CRISPRi to interrupt the
expression of long non-coding RNA (lncRNA) LOC646329 to reveal
its key function in the proliferation of radial glial cells. Luo et al.23
found that suppression of miR-199a/214 cluster could signiﬁcantly
increase the tumor tropism in human iPSC-derived neural stem cells
(NSCs). Similarly, CRISPRa may improve survivability of stem cells
by controlling their gene expression following transplantation.24
CRISPRi/a is highly speciﬁc in targeting human stem cells. Butapy: Nucleic Acids Vol. 9 December 2017 231
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Figure 2. Schemata of CRISPR/Cas9 Genome-
Editing System
gRNA contains a variable region (red nucleotides) and a
basic scaffold structure (blue nucleotides). The former is
complementary with one strand of targeted genome DNA
that should be adjacent to PAM (NGG, green one). The
basic scaffold nucleotide is then targeted to combine and
support Cas9 nuclease to generate gRNA/Cas9 com-
plexes. Finally, the targeted genome DNAwill be cut at the
third nucleotide from PAM (between G and C).
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Reviewbecause it targets transcription, it cannot be utilized in the study of
alternative splicing.
Genome-wide Screening. CRISPR/Cas9 has been used for genome-
wide and high-throughput genetic screening in mammalian cells.25,26
gRNA libraries have been generated to provide large volumes of genes
for analyzing results through sequencing data collection and offer an
alternative to the traditional RNAi library. Nonetheless, there may be
differences in the response of the gene regulatory network, because
RNAi knocks down gene expression at the mRNA level, whereas
CRISPR/Cas9 targets gene knockout or transcription inhibition.27
Technically, a virus mixture that contains thousands of gRNAs is pro-
duced to co-infect human stem cells with Cas9- or dCas9-expressed
virus to simultaneously target thousands of genes to screen for those
of interest. CRISPR/Cas9-mediated genome-wide screening strongly
supports the basic biological research of human stem cells. Shalem
et al.28 built a CRISPR/Cas9 lentiviral library to simultaneously knock
out 18,080 genes in human ESCs and identiﬁed many essential genes
that are involved in cell survival. Liu et al.29 identiﬁed 326 functional
loci of lncRNAs in human iPSCs using the CRISPRi lentivirus library.
It is clear that this genetic screening platform has the potential to
reveal novel functional genes and a particular signaling pathway,30
and should be a powerful platform for stem cell research.
Gene Knockin. Speciﬁc markers are extremely important for stem
cell research and indispensable during stem cell differentiation, trans-
plantation in vivo, and in vitro tracing. Normally, identiﬁcation of a
speciﬁc marker requires substantial time and energy, but CRISPR/
Cas9 has enabled vast improvements. It is now possible to easily
and rapidly create a speciﬁc marker by fusing epitope tags or ﬂuores-
cent proteins to the genes of interest.31,32With the exception of NHEJ,
homology-directed repair (HDR) is another mechanism by which
exogenous nucleotide sequences can be introduced into the genome
through homologous recombination.33 DSBs caused by CRISPR/
Cas9 signiﬁcantly promote the homologous recombination between
a targeted genome and exogenous DNA fragments to activate HDR232 Molecular Therapy: Nucleic Acids Vol. 9 December 2017at a cell level.9,34 For stem cell differentiation,
Adkar et al.35 used CRISPR/Cas9 to generate
a COL2A1-GFP reporter human iPSC line to
differentiate and purify chondrogenic cells by
fusing a GFP to COL2A1, which can co-express
GFP protein with COL2A1 protein. Similarly,Hunt et al.36 built a DARPP-32-GFP cell line to monitor the pharma-
cological proﬁle of striatal cultures in human medium spiny neurons
(MSNs).
Other Applications. Genomic imaging is indispensable to genetic
and cell biology study. CRISPR/Cas9 can also be used to visually
monitor the status of the genome during the cell cycle. Chen et al.37
modiﬁed the original nucleotide sequences of gRNA scaffold to
improve its binding ability with genome DNA, and fused the GFP
to the C terminus of dCas9 nuclease to ﬁnally form a live image to
monitor the dynamics of the genome in the cell cycle. This technique
can image ﬁxed or living cells with single or multiple colors. It may
also be used to monitor the genomic activity of stem cells. Anton
et al.38 imaged the chromatin of mouse ESCs using this method.
Disease Model and Drug Screening
Traditional animal disease models are important to human biological
and biomedical studies. Nonetheless, it is difﬁcult to simulate the real
situation in a human body because of species differences. Human
PSCs can overcome this limitation. CRISPR/Cas9 helps to easily
and rapidly introduce a gene mutation into human stem cells to
model a human disease, and avoids ethical problems and those asso-
ciated with species differences. Indeed, the CRISPR/cas9 system has
been shown to be an effective method for drug screening in human
stem cell disease models (Table 1).
Human PSCs. Human PSCs, including ESCs and iPSCs, are ideal
targets for gene knockout because they are easily expanded for further
experiments from a single cell culture after resistance selection
without losing their pluripotency.9 One straightforward strategy is
to knock out disease-relevant genes in human PSCs using CRISPR/
Cas9 in order to explore the pathogenic mechanism in the derived
cells (somatic cells, SSCs, and even tumor cells) and for drug
screening. Rb1 is known to initiate retinoblastoma in humans.39
RB1 null human ESCs generated by CRISPR/Cas9 showed aberrant
mitochondria and were shown by drug screening to be sensitive to
Table 1. Summary of CRISPR/Cas9 Utilized in Human Stem Cell Research
Cell Type Function Year References
Basic Biological Studies
Gene knockout
ESCs Mettl3erase m6A modiﬁcation leading to cell differentiation 2014 13
ESCs p53/63/73 knockout causes mesendodermal differentiation 2017 14
Control expression
ESCs downregulation of Oct4 leads to lineage differentiation 2014 18
iPSCs Dox-inducible CRISPRi represses gene expression 2016 19
PSCs Dox-inducible CRISPRa activates gene expression 2017 20
NSCs inhibition of miR-199a/214 increases tumor tropism 2016 23
Genome scale screening
ESCs identiﬁcation of essential genes for cell survival by knockout of 18,080 genes simultaneously 2014 28
iPSCs identiﬁcation of 326 functional loci of lncRNAs 2017 29
Gene knockin
iPSCs generation of collagen-GFP reporter for cell sorting 2016 35
ESCs monitor pharmacological proﬁles of striatal cultures using DARPP-32-GFP reporter cell 2017 36
Clinical Translational Studies
Disease model and drug
screening
ESCs RB1-null cells showed aberrant mitochondria and were sensitive to carboplatin (retinoblastoma) 2017 40
iPSCs isogenic iPSCs model for pathomechanism and drug screening (myelodysplastic syndrome) 2016 42
iPSCs point mutation iPSCs model for studying individual difference in hypoglycemia 2017 43
ESCs WRN-null hESCs model Werner syndrome (WS-iPSCs showed abnormal karyotypes seriously) 2015 44
organoids gene knockout kidney organoids showed cyst of tubules 2015 45
organoids modeling dyskeratosis congenita reveals the therapeutic functions of Wnt agonists 2016 49
organoids gene knockout intestinal organoids form tumors in mice kidney after subcapsule injection 2015 51
organoids organoids model reveals the function of APC and P53 in intestinal neoplasia 2015 52
organoids organoids model reveals the function of TGF-b in colorectal cancer (CRC) formation 2016 53
organoids combinatorial drug responses in organoids model (colorectal cancer [CRC]) 2016 54
Gene correction therapy
HSCs gene-corrected patient HSCs showed functional recovery in X-linked chronic granulomatous 2017 65
iPSCs gene-corrected patient iPSCs recovered b-globin (HBB) expression 2015 59
organoids gene-corrected patient organoids showed functional recovery in cystic ﬁbrosis 2013 50
HSCs gene-corrected patient HSCs recovered b-globin (HBB) expression in b-thalassemia 2016 61
iPSCs gene-corrected patient iPSCs showed functional recovery in hemophilia A 2015 63
iPSCs gene-corrected patient iPSCs showed normal phenotypes in Huntington’s disease 2017 64
Anti-virus therapy
T cells CXCR4-disrupted T cells showed HIV resistance 2015 69
HSCs CCR5-disrupted HSCs presented HIV resistance 2017 70
iPSCs CCR5-disrupted iPSCs and its derived blood cells showed HIV resistance 2015 71
iPSCs CCR5D32 iPSCs and its derived cells showed HIV resistance 2014 72
iPSCs CRISPR/Cas9-expressed iPSCs showed HIV resistance by elimination of virus RNA 2015 74
Anti-tumor therapy
CAR T cells the anti-tumor efﬁcacy of CAR T cells was enhanced through disrupting the PD-1 gene 2017 77
CAR T cells the anti-tumor efﬁcacy of CAR T cells was improved by fusing CD19 CAR to the TRAC gene 2017 78
iPSCs NK cells derived from ADAM17-disrupted iPSCs presented higher HIV resistance 2016 79
hESCs, human embryonic stem cells.
www.moleculartherapy.org
Reviewcarboplatin.40 Moreover, the isogenic human PSC knockout disease
model is crucial to eliminate the individual variations and unknown
gene mutations that occur during iPSC reprogramming.41 Chang
et al.42 demonstrated different drug responses among cells derived
from different patient-speciﬁc iPSCs and CRISPR/Cas9-generated
isogenic PSCs. Employing CRISPR/Cas9 can precisely introduce mu-
tations (point mutation, insertion, or deletion) into human PSCs togenerate gene mutant PSCs and provide a patient disease model. It
bypasses the limitations of iPSC generation that requires biopsy or re-
programming, and provides a strategy to determine precisely why
different patients with the same mutations present with different
features during pathogenesis. Guo et al.43 used CRISPR/Cas9 to
induce a point mutation (c.1288G>T) in the Men1 gene of normal
iPSCs to study the effect of individual differences in hypoglycemia.Molecular Therapy: Nucleic Acids Vol. 9 December 2017 233
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when use of patient-speciﬁc iPSCs is not appropriate or possible. For
example, Zhang et al.44 used WRN null human ESCs to model
Werner syndrome because patient-speciﬁc iPSCs showed abnormal
karyotypes. Taken together, CRISPR/cas9 technologies employed in
human PSCs can provide an array of genetically defective human dis-
ease models.41,45 Nonetheless, it is important to bear in mind that
PSC-derived somatic cells are young cells that more closely resemble
fetal cells.
Human SSCs. CRISPR/Cas9 can be used to manipulate human
SSCs including hematopoietic stem cells (HSCs), NSCs, and mesen-
chymal stem cells (MSCs).46–48 The challenge lies in obtaining a suf-
ﬁcient number of pure cells for diseasemodeling and drug screening if
these SSCs are difﬁcult to maintain or expand from a relatively small
number of cells. Use of the CRISPR/cas9 system has enabled many
genes in HSCs to be successfully manipulated.46 Unfortunately,
difﬁculties persist in the maintenance of these gene-manipulated
HSCs during selection, puriﬁcation, and expansion. These limitations
restrict the application of CRISPR/Cas9 in disease modeling and drug
screening.
Organoids. Human organoids are 3D cultures derived from human
PSCs, SSCs, or primary tissues. They have the ability of self-renewal
and can self-organize to be primary tissue-like clumps that contain
several kinds of cells. Hence they are regarded as better sources for
biomedical research than 2D human cell cultures. PSC-derived orga-
noids have been utilized to model human genetic disease and screen
drugs with the assistance of CRISPR/Ca9-mediated gene manipula-
tion. Basically, gene mutations are introduced into PSCs using
CRISPR/Cas9; then the engineered PSCs become gene mutant orga-
noids under 3D culturing conditions and can be used in disease
modeling and drug screening. Freedman et al.45 generated gene
mutant kidney organoids from knockout podocalyxin, PKD1 or
PKD2 genes of human ESCs using CRISPR/Cas9, which showed
abnormal features (junctional organization defects of podocyte-like
cells or cyst of kidney tubules). The DKC1 gene mutation causes
congenital dyskeratosis. Woo et al.49 generated intestinal organoids
from patient-speciﬁc iPSCs, both isogenic and gene-corrected orga-
noids, to reveal a feedback loop between the Wnt pathway and telo-
mere function. This also demonstrated the therapeutic action of Wnt
agonists in the treatment of congenital dyskeratosis.49 In addition,
CRISPR/Cas9 can be utilized to directly mediate gene manipulation
in SSCs or primary tissue-derived organoids. Their pluripotency
can be sustained well under 3D culture conditions when screening
the targeted colonies.50 This strategy has been proposed as a new plat-
form for cancer research. Matano et al.51 engineered normal human
intestinal organoids by knocking out several tumor suppressor genes
and oncogenes simultaneously, and showed formation of tumors
following subcapsular injection into the kidney. Similarly, Drost
et al.52 produced the most common mutant genes in intestinal orga-
noids to reveal the functions of APC and P53 genes in intestinal
neoplasia. Fessler et al.53 generated BRAFV600E mutant organoids to
explore the function of transforming growth factor b (TGF-b) in234 Molecular Therapy: Nucleic Acids Vol. 9 December 2017transforming sessile serrated adenomas (SSAs) into colorectal cancer
(CRC). SSCs or primary tissue-derived organoids can also be utilized
to screen anti-tumor drugs following the introduction of gene muta-
tions by CRISPR/Cas9. Verissimo et al.54 tested the combinatorial
drug response for treating CRC using RAS and KRAS gene mutant
normal and tumor organoids.
Stem Cell Therapy
DSB introduced by CRISPR/Cas9 signiﬁcantly promotes HDR in tar-
geted cells. Original stem cells can be easily remolded using these ge-
netic engineering techniques to generate new function-modiﬁed stem
cells for cell therapy. There is no doubt that CRISPR/Cas9 has signif-
icantly broadened the application of stem cells in human regenerative
medicine.
Gene Correction Therapy. Many gene mutations at the genome level
often result in genetic disorders. Although allografts have been widely
utilized in preclinical experiments and clinical cell therapy studies,
immune rejection remains a concern.55,56 CRISPR/Cas9-mediated
gene correction provides a new vision of cell therapy for many human
genetic diseases. The general strategy is to break the genomic DNA
near the targeted genes using CRISPR/Cas9 and simultaneously pro-
vide a donor that presents normal sequences. The mutant gene frag-
ments can be corrected through homologous recombination, and the
associated functional defect in the targeted cells is corrected. It has
been demonstrated in an animal model that gene correction offers
a deﬁnitive cure for genetic disease. Li’s group57 co-injected gRNA,
Cas9 nuclease, and healthy donor plasmid of the Crygc gene into
the zygotes of cataract mice and generated cataract-free mice. Pa-
tient-speciﬁc iPSCs are the most common source for gene correction
because they can be differentiated into all kinds of functional somatic
cells after gene correction. Gene-corrected b-thalassemia patient-spe-
ciﬁc iPSCs are able to restore HBB expression and be differentiated
into functional hematopoietic progenitor cells.58,59 Patient-speciﬁc
organoids offer a promising source for gene correction and are
more easily differentiated into somatic cells for transplantation
compared with PSPs. Schwank et al.50 successfully obtained function
recovered cells after they repaired the mutant CFTR gene in human
intestinal stem cell organoids. For therapeutic purposes, stem cells
should be maintained in a “stemness” state. Hence we normally do
not criticize the purity of manipulated cells, and use adeno-associated
virus (AAV) to deliver the donor for gene correction. Porteus’s
group60,61 ﬁnally obtained around 38% biallelic-corrected b-thalassa-
nemia HSCs using AAV-assisted gene correction after rough puriﬁca-
tion. This was sufﬁcient for cell transplantation and avoided the
difﬁculties caused by random integration in lentivirus or retrovirus-
meditated gene therapy.60,61 CRISPR/Cas9-mediated gene correction
has become a principal therapeutic strategy in the study of genetic
diseases such as b-thalassemia, Duchenne muscular dystrophy,
hemophilia A, Huntington’s disease, and X-linked chronic granulo-
matous disease.58,62–65 It should nonetheless be noted that although
we can obtain functionally recovered stem cells after gene correction
in vitro, their therapeutic safety and efﬁcacy after transplantation
remain to be evaluated.
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host cells during infection. As mentioned above, CRISPR/Cas9 can
help modify the targeted cells efﬁciently and easily. Hence infection
with HIV can be prevented by modifying the receptors of human
cells. For example, CCR5 and CXCR4 are co-receptors of human
white blood cells for HIV infection.66,67 There are reports showing
that CCR5- or CXCR4-disrupted human CD4+ T cells, HSCs
or iPSCs, present HIV resistance after CRISPR/Cas9-mediated
gene modiﬁcation.68–71 Nevertheless, cells acquired HIV resistance
through direct gene disruption, and some basic functions may also
have been affected. It may be advisable to ﬁrst deﬁne some natural
mutations that do not affect the host’s biological functions before
utilizing CRISPR/Cas9 to introduce desirable mutations (e.g., point
mutation) in cell engineering. Ye et al.72 introduced a natural muta-
tion (CCR5D32) into normal human iPSCs and ﬁnally obtained
HIV-resistant monocytes and macrophages after cell differentiation.
In addition, CRISPR/Cas9 has been demonstrated to be effective
in targeting the genetic material of viruses.73 Liao et al.74 engineered
human iPSCs to express HIV-targeted gRNA and Cas9 protein that
could protect cells from virus infection by disrupting the RNA of
HIV in iPSCs and their derived adult cells.
Anti-tumor Therapy. Genetically engineered human immune cells
and stem cells have already been widely used in anti-tumor research,
such as delivering anti-tumor proteins and inducing cancer cell
death.75 Chimeric antigen receptor (CAR) T cells are considered a
milestone in the cure of refractory blood cancer.76 CRISPR/Cas9
can be used to increase their anti-tumor efﬁcacy by disrupting the
programmed death protein 1 (PD-1) in CAR T cells by eliminating
PD-L1 (PD-1 ligand) expressed tumor xenografts in vivo.77 In addi-
tion, CRISPR/Cas9 can be utilized to eliminate the risks associated
with lentivirus-mediated CAR T cells, such as the potential of onco-
genesis and recovery of replication. Eyquem et al.78 engineered T cells
to express CAR uniformly by directly fusing CD19 CAR to cells’
TRAC gene and also increased their potency. For the treatment of
solid tumors, Blum et al.79 introduced the stable expression of
CD16a (S197P) and disrupted ADAM17 in human iPSCs that could
further differentiate into natural killer cells for anti-tumor therapeutic
research.
Challenges
Off-Target
A common problem of all gene manipulation techniques, including
CRISPR/Cas9 systems, is that they miss their target. The mismatch
between gRNA and genomic DNA is the main cause of non-speci-
ﬁcity in genome editing. It has been shown that Cas9 nuclease has
diverse tolerance to the mismatch between gRNA and targeted
genomic DNA. The PAMmismatch (e.g., RNG) can also lead to being
off-target.80,81 The ratio of being off-target is relative to the targeted
genes and hosts. For example, CRISPR/Cas9 can generate off-targets
at a different ratio for different genes (60% forHBB gene and 22% for
CCR5 gene) in the HEK293 cell line, while the ratio of off-targets is
just 0.34% for the RNF2 gene in the HeLa cell line.82,83 Off-targets
can also be identiﬁed in stem cells. Wu et al.84 revealed that off-targetsites were mainly related to genes in mouse ESCs. Fortunately, recent
whole-genome sequencing results have indicated that the incidence
of off-targets caused by CRISPR/Cas9 is very low in human stem
cells.85–87 Although some inaccuracy is inevitable, it can be controlled
or reduced using several common strategies.
Optimize gRNA Design. Well-designed gRNAs play very critical
roles in ensuring a high efﬁciency of genome cleavage and low inci-
dence of off-targets in human stem cell research. There are various
online tools for gRNA design that are user-friendly.88–94 When se-
quences of targeted genes are uploaded, all gRNAs that contain
PAM (NGG) will be generated automatically, and the possibility of
being off-targets is evaluated. Under normal circumstances, a higher
score means a lower possibility. Therefore, the gRNAs with high
scores are recommended in order to reduce the number of off-targets.
Nevertheless, deep sequencing or nuclease detection is required
to examine the incidence of off-targets in stem cells. Some studies
have shown that shorter gRNAs can reduce the occurrence of off-
target by reducing their mispairing with the targeted genome, but
the indels of on-target will also decrease accordingly, because binding
of shorter gRNAs to the targeted genome is not as stable as that of
longer ones.82,83
Modify Cas9 Nuclease or gRNA. Cas9 nickase (Cas9n) is a mutant
version of Cas9 that generates just a nick on the gRNA-bound strand
without breaking the whole double-strand DNA.95 This system needs
a pair of gRNAs to form two gRNA/Cas9n complexes for DNA cleav-
age and can dramatically decrease the off-target in human ESCs.96
Kleinstiver et al.97,98 modiﬁed the traditional Streptococcus pyogenes
Cas9 (SpCas9) to identify other PAM sequences or improve ﬁdelity.
Fu et al.99 reduced off-targets 5,000-fold by using truncated gRNAs.
Exploit Alternatives to Classic SpCas9. Type I and type III CRISPR-
Cas immune systems share a similar mechanism to type II. Tsai
et al.100 utilized a dimeric RNA to guide the highly speciﬁc cleavage
of FokI nucleases based on the classic CRISPR/Cas9 system. Cas3
and Cmr are nucleases of the type I and type III CRISPR-Cas
immune system and show better speciﬁcity than Cas9.101,102 More
encouragingly, no off-target has been detected using the CRISPR/
Cpf1 system.103,104
Editing Efficiency
Editing efﬁciency is another important aspect of gene manipulation
techniques. CRISPR/Cas9 has been widely utilized and has shown
high genome-editing efﬁciency in various mammalian cells.105 In
addition, the high editing efﬁciency can signiﬁcantly reduce costs
when processing stem cells in vitro. Nonetheless, its genome-editing
efﬁciency is insufﬁcient for human stem cell research and hampers
the transfer of genome editing from the bench to the bedside. For
example, a virus is commonly used for CRISPR/Cas9 delivery, but
this confers risks for the clinical transplantation of stem cells. It is
almost impossible for some stem cells, such as HSCs and MSCs, to
be expanded sufﬁciently for clinical application from screening a
single cell after the manipulation of CRISPR/Cas9.Molecular Therapy: Nucleic Acids Vol. 9 December 2017 235
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ing is related to gRNA expression and gRNA/Cas9 binding.106 Em-
ploying puriﬁed gRNA and Cas9 protein has been shown to directly
improve the genome-editing efﬁciency in human stem cells and pro-
vide more stable and sufﬁcient Cas9 nuclease for genome editing. Kim
et al.107 delivered puriﬁed gRNA and Cas9 into human H9 ESCs, and
ﬁnally achieved 23% indels, which was almost ﬁve times higher than
that reported by Mali et al.8 in 2013. Gundry et al.108 remarkably
enhanced the genome-editing efﬁciency of CRISP/Cas9 in human
HSCs using puriﬁed gRNA and Cas9 nuclease. This avoids the effect
of protein transcription and translation. In addition, editing efﬁciency
can be improved by controlling the delivery time of gRNA and Cas9
nuclease in 293 cells, and may also be appropriate for stem cells.109
Modify gRNAs or Cas9 Nucleases Artificially. Longer gRNA binds to
Cas9 nuclease more tightly with a consequent huge improvement in
genome-editing efﬁciency.105 Exogenous RNAs cannot stay long in
human cells because of RNA degeneration.110 Genome-editing efﬁ-
ciency can be improved if gRNA can be maintained for a longer
time prior to degradation. Hendel et al.111 utilized some chemical
groups to protect the phosphoramidites of gRNAs and signiﬁcantly
enhanced the genome-editing efﬁciency of CRISPR/Cas9 in T cells
and CD34+ HSCs. Other artiﬁcially modiﬁed Cas9 nuclease or
alternatives to CRISPR/Cas9 have also been reported to have greater
genome-editing efﬁciency, such as Cas3-CRISPR, type III-A CRISPR-
Cas-Csm, FokI-CRISPR, and Cpf1-CRISPR.100–102,104 Nonetheless,
stronger experimental evidence is required to support these alterna-
tives in stem cell studies.
Preprocess Host Cells. CRISPR/Cas9-mediated genome editing de-
pends on NHEJ and HDR. Yu et al.112 identiﬁed two compounds
(L755507 and brefeldin A) that improved genome-editing efﬁciency
by enhancing HDR efﬁciency in human PSCs. SCR7 is a small molec-
ular inhibitor of the NHEJ pathway.113 Zygotes treated with SCR7
showed a 19-fold improvement in gene knockin efﬁciency using
CRISPR/Cas9.114 Similarly, RS-1, an HDR enhancer, improved the
gene knockin efﬁciency 2- to 5-fold in mouse embryos.115 Other
bioactive proteins, such as E1B55K and E4orf6, can likewise increase
the knockin efﬁciency.116 Although the toxicity of these small mole-
cules and proteins requires extensive evaluation in human stem cells,
they provide invaluable information to improve the editing efﬁciency
of CRISPR/Cas9 in stem cell research.
Utilize Auxiliary Elements. Microhomology-mediated end joining
(MMEJ) is another DNA repairing system in cells.117 On this basis,
a precise integration into a target chromosome (PITCh) system has
been designed to improve the integration efﬁciency of gene knockin
using several gRNAs to cut genome and PITCh vectors.118 It is easier
during donor construction, because the PITCh vector needs only a
short micro homologous arm (5–25 bp) that can be synthesized
directly. In contrast, classical homologous arms normally comprise
thousands of base pairs of DNA ampliﬁed by PCR. Nonetheless,
more experimental evidence is required to support its use in human
stem cells. PiggyBac is a transposon system that can achieve change236 Molecular Therapy: Nucleic Acids Vol. 9 December 2017in position and insertion and deletion of DNA fragments from a
chromosome.119 It has been reported to dramatically increase
CRISPR/Cas9-mediated genome-editing efﬁciency in human PSCs
from the normal level of 1%–5% without using an integrated
screening cassette.58,120 Nonetheless, the random transposable action
of PiggyBac transposons needs to be evaluated.
Delivery Routes
The commercial CRISPR/Cas9 genome-editing system is generally
presented as plasmids, RNAs, or proteins. Nonetheless, this system
cannot be used for gene manipulation unless they can be delivered
into the targeted hosts. Selection of an appropriate delivery method
is thus vital for CRISPR/Cas9-mediated gene manipulations.
Normally, they have delivery strategies similar to other gene-
manipulating tools such as RNAi, ZFN, or TALEN. Nonetheless,
because of the unique features of human PSCs and SSCs in regen-
erative medicine, different delivery strategies need to be considered
carefully.
Transient Expression Strategies. Gene manipulation can be easily
achieved by transient transfections of gRNA/Cas9 nuclease-ex-
pressed plasmids or their puriﬁed synthetic products in common
cells.7,8,107,121 The situation becomes more complex in stem cell
studies as stem cells are more fragile, sensitive, or resistant to the tran-
sient delivery methods than common somatic cells and immortalized
cell lines. Hence appropriate delivery methods are required. In terms
of efﬁciency of delivery, micro-injection achieves the highest up to
100% for direct injection of substrates into targeted cells one by one
through glass micro-pipettes.122 But this micro-injection cannot be
applied for large-scale injections, and thus limits its application to
immortalized cells (e.g., PSCs).123 Both electrotransfection and nucle-
ofection have achieved high transfection efﬁciency in various human
stem cells. The former can treat more kinds of cells in principle, while
the latter presents higher cell viability after transfection.58,124–126 Mil-
lions of cells can be handled in one reaction based on electroporation;
nonetheless, much time and effort have been expended in purifying
the real transfected cells using selection cassettes.58,124 Lipidosome re-
agents are not as popular as the other three methods for human stem
cell transfection, because their transfection efﬁciency is poor when
targeting many human stem cell lines. In addition, many human
stem cell lines are extremely sensitive to the cytotoxicity of trans-
fection reagents and the mechanical damage that occurs during
cell pretreatments. Some new lipidosome-like delivery methods are
now available with CRISPR/Cas9. Yin et al.127 exploited a new lipid
nano-particle to deliver Cas9 mRNA for genome editing; Jiang
et al.128 optimized the formula using lipid-like nano-particles
(LLNs) for gRNA and Cas9 mRNA delivery. It has been noted that
some stem cell lines are sensitive and hard to be transfected.50
Lentivirus-Mediated Strategy. Lentivirus is another commonly used
vehicle for CRISPR/Cas9 delivery. It is more stable, more efﬁcient,
and can theoretically infect almost all kinds of human stem cells
in vivo and in vitro with high efﬁciency and low cellular
toxicity.37,129,130 It presents several remarkable advantages for stem
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introduce high, stable, and permanent expression of exogenous genes
for random genome integration, which is crucial for CRISPR imaging
and CRISPR screening when infecting human stem cells such as
human PSCs, SSCs, or organoids.18,29,37,38,131 Second, CRISPR-medi-
ated genetic screening needs lentivirus to deliver thousands of gRNAs
into stem cells with high efﬁciency and low cellular toxicity.25,132
Third, lentivirus is directly added for co-culturing with cells and elim-
inates the damage from cell pretreatment. Nonetheless, the random
genome integration remains an inevitable barrier that limits clinical
applications of lentivirus. Although lentivirus has been proven to be
an effective delivery vehicle to mediate genome editing in stem cells,
it is still not recommended for single or multiple gene manipula-
tions.133,134 Uncontrolled gene mutations introduced by random in-
tegrations are not desired, while integrase-defective lentivirus shows
a lower infection efﬁciency and gene expression level than the normal
lentivirus.135
AAV-Mediated Strategy. Theoretically, AAV supports all applica-
tions of the CRISPR/Cas9 gene manipulating system similar to
lentivirus (e.g., genome editing, CRISPRi/a, CRISPR imaging, and
so on) because it shares the advantages of lentivirus in stem cell
research.136,137 We can easily obtain extremely high titering AAV vi-
rus using helper plasmids during virus packaging with consequent
higher infection efﬁciency than lentivirus.138,139 More importantly,
an AAV-delivered donor is genome integration-free. It permanently
exists as episomal DNA in cells and largely promotes efﬁciency of
CRISPR/Cas9-mediated gene correction in stem cell therapy.140–142
For example, Tabebordbar et al.143 repaired mutant Dmd genes by
AAV-delivered CRISPR/Cas9 in muscle stem cells. Unfortunately,
the insert size capacity of AAV was far smaller than lentivirus.
With the exception of SaCas9 (Staphylococcus aureus), smaller nucle-
ases need to be exploited to enhance editing efﬁciency when choosing
AAV as the delivery vehicle.144 In addition, AAV-delivered gRNA
and Cas9 nuclease will be permanently expressed in all new divided
cells. This may induce undesired genome damage and ultimately
lead to cell death.145 Although this situation has been resolved by
delivering donor (AAV) and CRISPR/Cas9 (transient delivery
strategies) separately, the advantages of AAV are partly concealed.61
In addition, the immunogenicity of AAV remains another risk that
must be considered.146
Novel Delivery Strategies. With the development of CRISPR/Cas9,
some novel delivery methods have emerged that eliminate the toxic
effects or safety problems associated with transient transfection or vi-
rus infections. A chip containing micro-constrictions can generate
transient membrane holes on cells by mechanical deformation to
deliver CRISPR/Cas9 plasmids when the mixture of cells and plasmid
pass the chip rapidly.147 This method is reported to introduce high
efﬁciency in genome editing with low cell loss in hard-to-transfect
cells.147 Based on the membrane punching mechanism, it also
has the advantages and disadvantages of electroporation. The other
methods are to utilize cell-penetrating peptides (CPP) to conjugate
gRNA and Cas9 nuclease for CRISPR/Cas9 delivery in a plasmid-free, transfecting reagent-free, and virus-free manner.121 A disadvan-
tage is its relatively low transfection efﬁciency.
Prospects
Since its introduction in 2013, the CRISPR/Cas9 genome-editing
system has been rapidly developed and widely used in all human
stem cell studies. All gene-manipulating capacities (e.g., knockout,
knockin, knockdown, and expression activating) are incredibly inte-
grated in one technique. It is user-friendly, efﬁcacious, and econom-
ical such that genome manipulation ceases to be a challenge for new
researchers. Undoubtedly, the CRISPR/Cas9 genome-editing system
has revolutionarily changed the fundamental and translational
stem cell research. Although solutions are still required to reduce
the off-target effect, improve editing efﬁciency, and exploit novel
delivery strategies at a low cost and with high safety for clinical
stem cell studies, CRISPR/Cas9-mediated preclinical studies have
made remarkable progress and offer huge potential in human stem
cell and regenerative research.
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